# **Pharmacy and Therapeutics Committee Meeting Record**

**Date:** 3/17/06 **Time:** 9:00 a.m. – 4:00 p.m. **Location:** 3232 Elder Street, Conference Room D

**Moderator: Steve Montamat, M.D.** 

Committee Members Present: Catherine Gundlach, PharmD, Cindy Bunde, PA, Donald Norris, M.D., Phil Petersen, M.D., Richard Markuson, RPh, Rick Sutton, RPh, Stan Eisele, M.D., Steve Montamat, M.D., Tami Eide, Pharm D, Thomas Rau, M.D., William Woodhouse, M.D.

Others Present: Selma Gearhardt, PharmD, Steve Liles, PharmD, Bob Faller, Cindy Brock

Committee Members Absent: Robert Comstock, RPh

AGENDA ITEMS	PRESENTER	OUTCOME/ACTIONS
CALL TO ORDER	Steve Montamat, M.D.	Dr. Montamat called the meeting to order.
Introductions		Dr. Montamat introduced Dr. Donald Norris, the new Medicaid Medical Director and Robert Faller, Pharmacy Medical Program Specialist to the committee.
<b>Committee Business</b>	Steve Montamat, M.D.	Dr. Montamat called the roll. One voting member was absent.
<ul><li>Roll Call</li><li>Reading of Confidentiality</li></ul>	Steve Montamat, M.D.	Dr. Montamat read the confidentiality statement.
Statement  Approval of Minutes from January 20, 2006 Meeting	Steve Montamat, M.D.	The minutes from the January 20, 2006 Committee meeting were approved.
<ul><li>Review of Key</li><li>Questions</li></ul>	Steve Montamat, M.D.	Targeted Immune Modulators #1 update Psorasis was added as a diagnosis.

		Inhaled Beta 2 Antagonists #3 update Review w/same key agents and key questions  Second Generation Antidepressants #3 update No additions or deletions  Triptans #4 update No new agents same key questions
Targeted Immune Modulators	Selma Gearhardt, PharmD	Dr. Gearhardt presented a review of the Targeted Immune Modulators. Her presentation included a quick review of traditional DMARD's and data on the indications, pharmacology, pharmacokinetics, adverse effects, black box warnings, interactions, and contraindications in the Targeted Immune Modulators.  Drugs included:  infliximab (Remicade®) etanercept (Enbrel®) adalimumab (Humira®) anakinra (Kineret®) efalizumab (Raptiva®) alefacept (Amevive®)
Public Comment Period	Steve Montamat, M.D.	17 people signed up to speak during the public comment period. Public comment was received from the following:  Dr. Robert Calder speaking for Merck on Cozaar/Emend Jason Alm speaking for Sankyo/Forrest on Benicar/Benicar HCT Dr. Andy Weis speaking for Novartis on Diovan

Hyperplasia (BPH) Agents		precautions, AUA guidelines, beneficial/adverse effects provided through a review of clinical trial data. The agents reviewed included:  alfuzosin (Uroxatral®) doxazosin (Cardura®) tamsulosin (Flomax®) terazosin (Hytrin®) dutasteride (Avodart®) finasteride (Proscar®)
Drug Class Review  Newer Antiemetics	Tami Eide, PharmD	Dr. Eide presented a review of the Newer Antiemetics Her presentation included data on the indications, off label uses, pharmacology, pharmacokinetics, adverse effects, interactions and contraindications.
		Drugs included:  Aprepitant (Emend®) Dolasetron (Anzemet®) Granisetron (Kytril®) Ondansetron (Zofran®) Palonosetron (Aloxi®)
Review Clinical Data  Newer Antiemetics	Kimberly Peterson, MS	Ms. Peterson presented data on the, efficacy, adverse events, tolerability, prevention of N/V and safety of Newer Antiemetics provided through a review of clinical trial data. The agents reviewed included:  aprepitant (Emend®) dolasetron(Anzemet®) granisetron (Kytril®) ondansetron (Zofran®) palonosetron (Aloxi®)
Review of Clinical Data	Susan Carson, MPH	Ms. Carson presented updated data (update #3) on the healing of esophagitis or relief of symptoms; maintenance of healed esophagitis;

Proton Pump Inhibitors		healing rates, differences in efficacy and evidence of adverse events, and safety of Proton Pump Inhibitors provided through a review of clinical trial data. The agents reviewed included:  esomeprazole magnesium (Nexium®) lansoprazole (Prevacid®) omeprazole (Prilosec®; Zegerid®) pantoprazole (Protonix®) rabeprazole (Aciphex®)
Review of Clinical Data  Angiotensin- 2 Receptor Antagonists	Mark Helfand, MD, MPH	Dr. Helfand presented updated data (update #1) on the Angiotensin II Receptor Antagonists. He highlighted changes since the last review and updates in national guidelines for heart failure. His review included: comparative effectiveness, adverse effects, safety and efficacy of the following agents:  candesartan (Atacand®) eprosartan (Teveten®) ibesartan (Avapro®) losartan (Cozaar®) olmesartan (Benicar®) yelmisartan (Micardis®) valsartan (Diovan®)
Review of Clinical Data  Ace Inhibitors	Mark Helfand, MD, MPH	Dr. Helfand presented updated data (update #2) on the ACE Inhibitor class. His review included: outcomes, safety/efficacy and adverse events of the following agents:  benazepril (Lotensin®) captopril (Capoten®) enalapril (Vasotec®) fosinopril (Monopril®) lisonopril (Prinivil®, Zestril®) moexipril (Univasc®)

		perindopril (Aceon <sup>®</sup> ) quinapril (Accupril <sup>®</sup> ) ramipril (Altace <sup>®</sup> ) trandolapril (Mavik <sup>®</sup> )
Committee Clinical Discussions and Conclusions		Targeted Immune Modulators  Based on the evidence that was presented, the Committee consensus was that they would like to recommend PA criteria to include: therapeutic guidelines for diagnosis.
		BPH Drugs Based on the evidence that was presented, including the implementation of Medicare Part D, the Committee would not make any recommendations at this time.
		Newer Antiemetics Based on the evidence that was presented, the Committee consensus was to leave the PA criteria as it currently exists.
		Proton Pump Inhibitors  Based on the evidence that was presented, the Committee consensus was to not make any changes at this time based on therapeutics.
Public Meeting Adjourned		
Closed Executive Session	Randy May, Chief Deputy Administrator	Mr. May presented the financial data on the selected drug classes.
Committee Final Recommendation for Therapeutic Classes	Steve Montamat, MD	<ul> <li>Targeted Immune Modulators</li> <li>The Committee recommended Amevive® (alefacept), Enbrel® (etanercept), Humira® (adalimumab), Kineret® (anakinra), Raptiva® (efalizumab) and Remicade® (infliximab) all be designated as preferred agents.</li> <li>The Committee recommended no non-preferred agents.</li> </ul>

### **Newer Antiemetics**

- The Committee recommended Zofran® (ondansetron) be designated as a preferred agent.
- The Committee recommended Anzemet ® (dolasetron), Emend® (aprepitant) and Kytril® (granisetron) be designated as non-preferred agents and require prior authorization.
- No recommendations were made for Aloxi® (palonosetron).
- Current therapeutic prior authorization criteria will remain.

## **Proton Pump Inhibitors**

- The Committee recommended Nexium® (esomeprazole), Prevacid® (lansoprazole) capsules and granules for solution and Prilosec® OTC (omeprazole) be designated as preferred agents.
- The Committee recommended Aciphex<sup>®</sup> (rabeprazole), omeprazole, Prevacid<sup>®</sup> SoluTab (lansoprazole), Prilosec<sup>®</sup> (omeprazole), Protonix<sup>®</sup> (pantoprazole), Zegerid <sup>®</sup> (omeprazole) be designated as non-preferred agents and require prior authorization.
- Current therapeutic prior authorization criteria will remain.

#### Benign Prostatic Hyperplasia (BPH) Treatment Agents

- The Committee recommends Avodart<sup>®</sup> (dutasteride), doxazosin (generic), Flomax<sup>®</sup> (tamsulosin), Proscar<sup>®</sup> (finasteride), terazosin (generic) and Uroxatral<sup>®</sup> (alfuzosin) be designated as preferred agents.
- The Committee recommends Cardura<sup>®</sup> (doxazosin) and Hytrin<sup>®</sup> (terazosin) be designated as non-preferred agents and require prior authorization.

## **Angiotensin-2 Receptor Antagonists**

• The Committee recommends Avapro<sup>®</sup> (irbesartan), Benicar<sup>®</sup> (olmesartan), Cozaar<sup>®</sup> (losartan), Diovan<sup>®</sup> (valsartan) and Micardis<sup>®</sup> (telmisartan) be designated as preferred agents.

• The Committee recommends Atacand® (candesartan) and Teveten® (eprosartan) be designated as non-preferred agents and require prior authorization.

# **Angiotensin Converting Enzyme Inhibitors**

- The Committee recommends Altace<sup>®</sup> (ramipril), captopril (generic), captopril/hydrochlorthiazide (generic), enalapril (generic), enalapril/hydrochlorthiazide (generic), lisinopril (generic) and lisinopril/hydrochlorthiazide (generic) be designated as preferred agents.
- The Committee recommends Accupril® (quinapril), Accuretic® (quinapril/hydrochlorthiazide), Aceon® (perindopril), benazepril, (generic) benazepril/hydrochlorthiazide (generic), Capoten® (captopril), Capozide® (captopril/hydrochlrthiazide), fosinopril, fosinopril/hydrochlorthiazide, Lotensin® (benazepril), Lotensin- HCTZ® (benazepril/ hydrochlorthiazide), Mavik® (trandolapril), moexipril, Monopril® (fosinopril), Monopril-HCTZ®

(fosinopril/hydrochlorthiazide), Prinivil <sup>®</sup> (lisinopril), Prinzide <sup>®</sup> (lisinopril/hydrochlorthiazide), quinapril, quinaretic, Uniretic <sup>®</sup> (moexipril/hydrochlorthiazide), Univasc <sup>®</sup> (moexipril), Vasorectic <sup>®</sup> (enalapril/hydrochlorthiazide), Vasotec <sup>®</sup> (enalapril),

Zestoretic <sup>®</sup> (lisinopril/hydrochlorthiazide and Zestril <sup>®</sup> (lisinopril) be designated as non-preferred agents and require prior authorization.